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JAK2
V617F mutation is the most common somatic event observed in patients with myeloproliferative neoplasms (MPN).
1-4 JAK2
V617F
is found in over 95% of patients with polycythemia vera (PV), 55% of essential thrombocytosis and 65% of primary myelofibrosis (MF). Homozygous JAK2 V617F is present in about half of PV patients, whereas it is rarely seen in other MPNs. 3, 5, 6 Patients bearing homozygous JAK2 V617F tend to have a longer duration of disease, 2 higher hemoglobin levels, increased incidence of pruritis 7 and are more likely to progress to post-PV MF. 8 Homozygous JAK2 V617F is shown to result from mitotic recombination, leading to acquired uniparental disomy (aUPD) on chromosome 9p. 9 It was reported that JAK2 46/1 (GGCC) haplotype may predispose carriers to JAK2 mutation, [10] [11] [12] and JAK2
facilitates the acquisition of homozygous JAK2. 9, 13 Challenging this view was a single study reporting 9p aUPD in two PV subjects with wild-type JAK2, 14 suggesting that in these two individuals, 9p aUPD might have preceded JAK2
V617F . However, the relationship between JAK2 V617F and 9p aUPD, the frequency and stability of existing PV genotypes has yet to be systematically defined in a larger PV cohort. To address this, we performed whole-exome sequencing and SNP array in 31 PV patients, and further validated our findings in two additional cohorts totaling 59 patients (Supplementary Methods). In addition, we investigated the stability of PV genotypes using 36 longitudinal samples.
The allelic fraction of JAK2 V617F in granulocytes (GNC), measured by sequencing, varied from 0.01 to 1.0 (Figure 1 ). 9p aUPD spanning JAK2 locus was present in 48% of patients in the discovery set. The fraction of genomes harboring 9p aUPD in a given GNC sample, varied from 0.08 to 1.0 (Figure 1 ). On the basis of quantitative relationship between JAK2 V617F allelic fraction and the fraction of genomes harboring 9p aUPD, we defined four PV subgroups and validated this finding in extended two cohorts (Figure 1 ). Across the three cohorts, 42% of patients harbored JAK2 V617F in a heterozygous state without detectable 9p aUPD (subgroup I); 45% of patients had JAK2
V617F with an allelic fraction in direct proportion to the level of 9p aUPD (subgroup II; homozygous JAK2 V617F ); 10% of patients harbored 9p aUPD at approximately twice the level of the JAK2 V617F allelic burden (subgroup III; aUPD with heterozygous JAK2 V617F ). Although any single patient in subgroup III, taken in isolation, could be explained as a mixture of cells from subgroups I and II, the best explanation for the pattern of subgroup III across these patients is that JAK2
V617F and 9p aUPD reside in the same cell with heterozygous JAK2
V617F in all such patients. Thus, subgroup III reported in this study comprises a novel subtype that has not been previously described. Three patients (3%) exhibited trisomy of 9p, generating two copies of JAK2 V617F allele (subgroup IV). The number of patients in subgroup IV was too small and thus this group was not evaluated further.
We then investigated the stability of each PV genotype using longitudinal samples. The JAK2 V617 :9p aUPD ratio remained stable in 11 of 17 patients, although the JAK2 V617 allele burden Validation study 1 (n=40) Validation study 2 (n=19) Figure 1 . The mutational pattern of JAK2 V617F and 9p aUPD. The mutational pattern of JAK2 V617F and 9p aUPD in the discovery study (n ¼ 31) and two validation studies obtained from the archived PV DNA specimen from the same institution (n ¼ 40 and n ¼ 19, respectively) has been shown. I, II, III indicates three subgroups defined by the mutational pattern. Two patients in the discovery study with triploid JAK2 was excluded from the analysis. Black dots and open circles, DNA copy-number status determined by Affymetrix Genome-Wide Human SNP Array 6.0 (Santa Clara, CA, USA). Cross, DNA copy-number status determined by the Human610-Quad BeadChip (Illumina, San Diego, CA, USA). P-values of Pearson's correlation test were shown. Line fit was done by JMP Pro 10 software (www.jmp.com). (Figures 2d and e) . The subgroup-II clone in PV2 was eliminated, and a new subgroup-III clone emerged. It was interesting that PV28 and PV31 transformed to MF, whereas none of the other 14 patients with stable or progressed JAK2 genotype showed phenotype transformation. It has been suggested that patients with homozygous JAK2 V617F were more likely to develop post-PV MF, 2 a propensity we also observed in the subgroup-II patients (Supplementary Figure 1) . Among those 11 subgroup-II patients who transformed to MF, we have longitudinal samples collected for two patients PV28 and PV31. We observed that, in both patients, there was an outgrowth of a new subgroup-I clone (Figure 2d ). However, we could not establish the sequential order of these two events.
We propose four pathways leading to PV (Figure 2f ) to explain these results. PV stem cells or their self-renewing progenitors, in the majority of patients, acquire JAK2 V617F first. Approximately half of them remain stable in this configuration (subgroup I). Others in this pathway duplicate JAK2 by one of two different mechanisms: a minor fraction duplicated JAK2 V617F -bearing chromosome to produce trisomy 9p (subgroup IV). Almost half of the patients in subgroup I duplicate JAK2 V617F allele via mitotic recombination to produce 9p aUPD (subgroup II). We observed progression from subgroup I to II in two patients, but the factors controlling the progression could not be ascertained by our analysis. Ten percent of patients acquire 9p aUPD first followed by JAK2 V617F mutation, yielding patients in subgroup III. Although the 9p aUPD cell with wild-type JAK2 has been reported in one case study, 14 we did not observe 9p aUPD alone in our unselected three cohorts, suggesting it might be asymptomatic until acquisition of JAK2 V617F . However, we found that, in a single female patient who was not included in these three cohorts, her GNC showed almost complete 9p aUPD with a low JAK2 V617F allelic burden (0.24), indicating the majority of PV clone was composed of 9p aUPD (Supplementary Figure 2) . Further, this female was heterozygous for X-chromosome FHL1 gene and her GNC were clonal using a transcriptional clonality assay confirming that these aUPD changes represent subclonal evolutions of the original PV clone. 15 This patient is probably in a transient state from 9p aUPD with wild-type JAK2 to subgroup III. As we observed more patients in subgroup III, it suggests that acquiring the JAK2 V617F mutation would provide a proliferative advantage. It was reported that JAK2 46/1 (GGCC) haplotype may predispose carriers to JAK2 mutation, 10-12 but we did not observe any significant difference in the frequency of this haplotype across three subgroups (Supplementary Figure 3) .
The 9p aUPD region, in any given patient, includes many genes (Supplementary Figure 4) . In the mitotic recombination event(s) leading to generation of aUPD, both common and rare alleles may be lost. We reasoned that genes with recurrent loss of wild-type alleles within aUPD regions underwent selection for the PV phenotype. Forty-eight genes lost their wild-type alleles in at least three patients (Supplementary Figure 5) . Among them, nine genes were related to cell division, seven in transcriptional regulation, four in epigenetic regulation and three genes were potential tumor suppressors. KDM4C and SMARCA2, which are involved in histone modification and chromatin remodeling, are among them. Moreover, 6 of the top 10 genes (Supplementary Table 1 ) have a functional role in regulation of cell division. Among them, DOCK8, a gene involved in intracellular signaling networks also had a somatic loss-of-function mutation and a novel germline variant. Recent evaluation of recurrent loss of heterozygosity in 3131 tumors in the absence of clear driver mutations led Elledge and coworkers to hypothesize the existence of cancer gene islands. 16 These are regions harboring multiple cancer genes that act in a coordinated manner within the cancer cell to produce a strong tumorigenic effect. Thus, our observations may suggest that genes in 9p aUPD region other than JAK2 could also contribute to PV pathophysiology.
Heretofore, the zygosity of the JAK2 V617F has been estimated by the allele burden with an arbitrary threshold of 40.5 for homozygous and o0.5 for heterozygotes. This approach assumed a pure tumor cell population, which often is not the case. In this study, we account for tumor cell purity by comparing JAK2 V617F with the level of 9p aUPD in the cell, rather than the absolute allele burden, leading to more accurate determination of mutant JAK2 zygosity. With this more accurate measure of JAK2 mutant zygosity, we observe that most patients can be classified in to one of three subgroups (Figure 1) , setting the stage for more precise analysis of prognostic value of JAK2 zygosity, as well as improved resolution of the clonal status of a patient's tumor.
For the first time, we investigated the clonal stability of these PV genotypes. Two-thirds of the patients were apparently stable in their PV clone for at least 2 years. Patients of all subgroups were represented among the stable patients. One-third of the patients exhibited clonal changes, with emergence of both prognostically more or less favorable JAK2 V617F patterns (Figures 2b-e) . However, our samples size is too small to investigate the factors controlling the stability of clones but the role of treatment regimen in clonal stability is clearly an important question. Further study of the clinical properties of a larger cohort of subgroup III patients, compared with subgroup I and II, is required to elucidate the contribution of 9p and the cancer genes therein in PV pathogenesis. This novel perspective on the molecular basis of the evolution of PV should lead to a better understanding of the roles of JAK2 V617F and 9p aUPD in this disease.
Therefore, current research efforts are focused on more effective and less toxic targeted therapies, which will require an improved understanding of the molecular events underlying these malignancies. Janus kinase 3 (JAK3) is constitutively activated in a number of T-cell malignancies and has emerged as a molecular target for cancer therapy.
3-5 JAK3 belongs to a family of cytoplasmic non-receptor tyrosine kinases (JAK1, JAK2, JAK3 and TYK2) that mediate signals initiated by cytokine and growth factor receptors. 6 Although JAK1, JAK2 and TYK2 are ubiquitously expressed, JAK3 is primarily confined to the hematopoietic lineage, where it has a vital role in lymphoid cell development and homeostasis. 7 Its restricted expression and critical function in lymphoid cells has attracted significant attention in recent years as a therapeutic target for immune-mediated diseases; 8 however, achieving JAK3 selectivity has remained a significant challenge. 9 The first-in-class JAK3 inhibitor, tofacitinib, has been hindered by undesirable pan-JAK inhibitory side effects that include anemia and neutropenia, presumably related to JAK2 inhibition and interference with cytokines such as erythropoietin and colony-stimulating factors. 10, 11 Thus, although efficacy of a next-generation JAK3 inhibitor is paramount, drug selectivity to JAK3 over JAK2 may determine its clinical usefulness.
By a series of structure-activity relationship studies based on the chemical scaffold of the established JAK3 inhibitor NC1153, 12 we identified a novel, stable, selective and efficacious inhibitor of JAK3 that was designated EP009 (Figure 1a,  Supplementary Figure S1 ). In vitro kinase assays revealed EP009 to be a low micromolar inhibitor of JAK3 (Figure 1b) with limited off-target effects against a panel of 92 human kinases (Supplementary Table S1 ). The interleukin (IL)-2-dependent T-cell line Kit225 and the IL-3-dependent pro-B-cell line BaF/3 were utilized to test EP009 specificity for JAK3 versus JAK2, respectively. In Kit225 cells, EP009 reduced IL-2-mediated JAK3 tyrosine phosphorylation with a cellular IC50 between 10 and 20 mM (Figure 1c, upper panel) . In contrast, EP009 had no detectable effect on IL-3-induced JAK2 tyrosine phosphorylation in BaF/3 cells up to 50 mM (Figure 1c, lower panel) . In addition, EP009 treatment reduced Kit225 cell viability with a LD50 of 5.0 mM at 72 h, whereas no effect on BaF/3 cell viability was detected (Figure 1d ). Structure-activity relationship studies revealed that deletion of the C12 methylene or substitution at the C2 hydroxymethyl groups of the cyclododecanone ring significantly reduced the efficacy of EP009 (Supplementary Figure S2) . Under the same experimental conditions, JAK inhibitors such as tofacitinib (CP-690,550) and ruxolitinib (INCB-18424) reduced both Kit225 and BaF/3 cell viability (Supplementary Figure S3) . Thus, although the IC50 values suggest that EP009 is not as potent as other JAK inhibitors, the degree of kinase selectivity differentiates it from what is typically obtained from an ATP-competitive inhibitor. Ongoing studies seek to delineate the underlying mechanism of JAK3 inhibition by EP009 through the application of biochemical, biophysical and structural studies.
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